journal
https://read.qxmd.com/read/38597742/cost-effectiveness-analysis-3l-of-axicabtagene-ciloleucel-vs-tisagenlecleucel-and-lisocabtagene-maraleucel-in-japan
#1
JOURNAL ARTICLE
Saaya Tsutsué, Shinichi Makita, Hiroya Asou, Hiroyuki Matsuda, Reiko Yamaura, Todd D Taylor
Aim: Cost-effectiveness analysis (CEA) was performed to compare axicabtagene ciloleucel (axi-cel) with tisagenlecleucel (tisa-cel) and lisocabtagene (liso-cel) for treatment of relapsed or refractory large B-cell lymphoma in adult patients after ≥2 lines of therapy in Japan. Materials & methods: Cost-effectiveness analysis was conducted using the partition survival mixture cure model based on the ZUMA-1 trial and adjusted to the JULIET and TRANSCEND trials using matching-adjusted indirect comparisons...
April 10, 2024: Future Oncology
https://read.qxmd.com/read/38597713/pembrolizumab-plus-chemotherapy-for-first-line-treatment-of-advanced-triple-negative-breast-cancer
#2
REVIEW
Amin Haiderali, Min Huang, Wilbur Pan, Katherine G Akers, Dylan Maciel, Andrew M Frederickson
Aim: A systematic review and network meta-analysis (NMA) was performed to evaluate the efficacy of first-line treatments for locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) patients. Materials & methods: Databases were searched for randomized controlled trials evaluating first-line treatments for locally recurrent unresectable or metastatic TNBC patients. NMA was performed to estimate relative treatment effects on overall and progression-free survival between pembrolizumab + chemotherapy and other interventions...
April 10, 2024: Future Oncology
https://read.qxmd.com/read/38592002/study-design-for-destiny-breast-respond-her2-low-europe-t-dxd-in-patients-with-her2-low-advanced-breast-cancer
#3
REVIEW
Valentina Guarneri, José Luís Passos Coelho, Francois P Duhoux, Daniel Egle, José Ángel García-Sáenz, Frédérique Penault-Llorca, Katri Selander, Hans Wildiers, Khalil Zaman, Petra Laeis, Markus Lucerna, Jean-Yves Pierga
Trastuzumab deruxtecan (T-DXd) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). Results on T-DXd treatment in HER2-low mBC have so far been limited to clinical trials. DESTINY-Breast Respond HER2-low Europe (NCT05945732) is a multi-center, multi-country, observational, prospective, non-interventional study planning to enroll 1350 patients from 216 sites receiving T-DXd or conventional chemotherapy as their routine clinical care for advanced stage breast cancer in 12 European countries...
April 9, 2024: Future Oncology
https://read.qxmd.com/read/38591950/immunotherapy-combined-with-cranial-radiotherapy-for-driver-negative-non-small-cell-lung-cancer-brain-metastases-a-retrospective-study
#4
JOURNAL ARTICLE
Shuangqing Lu, Xiaokang Guo, Zhengqiang Yang, Yulan Sun, Jiling Niu, Xuquan Jing, Hui Zhu
Background: This study assesses immune checkpoint inhibitors' efficacy for non-small-cell lung cancer (NSCLC) with brain metastases (BM) and explores the role of cranial radiation therapy (CRT) in the immunotherapy era. Methods: The retrospective analysis screened NSCLC patients with BMs from July 2018 to December 2021. Treatment involved chemotherapy combined with immune checkpoint inhibitors as the first-line, with patients divided into CRT and non-CRT groups. Overall survival (OS), progression-free survival and intracranial progression-free survival were calculated and compared...
April 9, 2024: Future Oncology
https://read.qxmd.com/read/38587388/the-impact-of-myelosuppression-on-quality-of-life-of-patients-treated-with-chemotherapy
#5
REVIEW
Jeffrey Crawford, Dana Herndon, Katerina Gmitter, Jared Weiss
Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia increases infection risk, and anemia frequently results in debilitating fatigue. Additionally, the bleeding risk associated with thrombocytopenia can lead to fear and anxiety. However, traditional interventions for myelosuppression fall short of the ideal. Granulocyte colony-stimulating factors reduce the risk of severe neutropenia but commonly lead to bone pain. Erythropoiesis-stimulating agents are not always effective and may cause thromboembolic events, while transfusions to correct anemia/thrombocytopenia are associated with transfusion reactions and volume overload...
April 8, 2024: Future Oncology
https://read.qxmd.com/read/38573230/real-world-evidence-in-the-reassessment-of-oncology-therapies-payer-perceptions-from-five-countries
#6
JOURNAL ARTICLE
Murtuza Bharmal, Ioannis Katsoulis, Jane Chang, Alex Graham, Apostolina Stavropoulou, Priti Jhingran, Chris L Pashos
Aim: This study explored the perceived value of real-world evidence (RWE) in the reassessment of oncology therapies by collecting the perspectives of health technology assessment/payer decision-makers. Materials & methods: A web-based survey was conducted using the Market Access Transformation Rapid Payer Response online portal. 30 participants from France, Germany, Spain, the UK and the USA were recruited based on their expertise. Results: Participants agreed that the most common uses of RWE are to confirm efficacy and safety results from randomized controlled trials and to reevaluate the projected utilization of an oncology therapy...
April 4, 2024: Future Oncology
https://read.qxmd.com/read/38573183/preclinical-and-phase-i-studies-of-an-antisense-oligonucleotide-drug-targeting-igf-1r-in-liver-cancer
#7
JOURNAL ARTICLE
Yonggang Li, Zhe Xu, Yuanyuan Li, Tianjun Jiang, Fanping Meng, Junliang Fu, Lei Huang, Fengchao Wang, Xia Wang, Fusheng Wang
Aim: To evaluate a novel antisense oligonucleotide drug targeting human IGF-1R in preclinical and phase I studies of liver cancer. Materials & methods: The tolerability and safety of an investigational new drug were evaluated in a dose-escalation trial involving 17 patients with advanced liver cancer after preclinical assessment of pharmacokinetics and pharmacodynamics. Results: The drug exposure levels in the phase I trial were determined by the in vivo efficacy with pharmacokinetics evaluation in rats and rhesus monkeys...
April 4, 2024: Future Oncology
https://read.qxmd.com/read/38573132/patient-engagement-in-designing-and-publishing-research-in-prostate-cancer-a-scoping-review
#8
REVIEW
Linda Sutton, Matthew Labriola, Thomas Bognanno, Shelby Moneer, Jennifer Ghith, Gustavo Rodriguez, Latorya Moore, Obaro Evuarherhe, Alicia K Morgans
Patients with cancer have the unique ability of being able to offer valuable insights into how cancer therapeutics may impact the overall patient experience and improve clinical outcomes. Patient engagement could therefore contribute to tailoring treatment strategies and research design according to patient needs. This study evaluated patient engagement in prostate cancer research by identifying patient input in the prostate cancer literature. We performed a keyword cluster analysis of articles from multiple databases and congresses in which patients provided input on disease management or were involved in study design, manuscript authorship or presentation of results (patient voice)...
April 4, 2024: Future Oncology
https://read.qxmd.com/read/38547003/plain-language-summary-of-the-transform-study-primary-analysis-results-liso-cell-as-a-second-treatment-regimen-for-large-b-cell-lymphoma-following-failure-of-the-first-treatment-regimen
#9
REVIEW
Jeremy S Abramson, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar
WHAT IS THIS SUMMARY ABOUT?: People diagnosed with a disease called large B-cell lymphoma (LBCL) may experience return, or early relapse, of their disease within the first year after receiving and responding to their first (first-line) treatment regimen. Others may have primary refractory disease, meaning that the disease either did not respond to first-line treatment at all or only responded for a very brief period. Second (second-line) treatment includes immunotherapy followed by high-dose chemotherapy and ASCT, which has the potential to cure LBCL...
March 28, 2024: Future Oncology
https://read.qxmd.com/read/38536033/treatment-outcomes-in-older-patients-with-metastatic-breast-cancer-receiving-palbociclib-plus-an-aromatase-inhibitor-a-plain-language-summary
#10
REVIEW
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Hope S Rugo
WHAT IS THIS SUMMARY ABOUT?: This summary describes an article published in the medical journal Frontiers in Oncology in September 2023. The article reports results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer. HR+/HER2- stands for hormone receptorpositive/human epidermal growth factor receptor 2-negative. This study evaluated whether older patients with this type of cancer benefited from the combination of two medicines - palbociclib and an aromatase inhibitor - compared with taking an aromatase inhibitor alone...
March 27, 2024: Future Oncology
https://read.qxmd.com/read/38517416/prolonging-the-lives-of-african-americans-with-metastatic-breast-cancer-by-adding-palbociclib-to-an-aromatase-inhibitor-in-routine-clinical-practice-a-plain-language-summary-of-a-real-world-database-study
#11
REVIEW
Hope S Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Tiah Tomlin-Harris, Adam Brufsky
WHAT ARE THE KEY TAKEAWAYS?: This study used de-identified medical information from the Flatiron Database. This database contains healthcare information on people with cancer treated by doctors in the United States but personal information is removed to maintain privacy. Medical information for people who received certain treatments in routine clinical practice or real-world setting was included in the study. This study showed that in the real-world setting, African-Americans with HR+/HER2- MBC lived longer when receiving palbociclib with an AI than with an AI alone...
March 22, 2024: Future Oncology
https://read.qxmd.com/read/38501262/progression-free-survival-and-safety-at-3-5%C3%A2-years-of-follow-up-results-from-the-randomized-phase-3-prima-engot-ov26-gog-3012-trial-of-niraparib-maintenance-treatment-in-patients-with-newly-diagnosed-ovarian-cancer-a-plain-language-summary
#12
REVIEW
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O'Cearbhaill, Izabela A Malinowska, Luda Shtessel, Natalie Compton, Mansoor R Mirza, Bradley J Monk
WHAT IS THIS SUMMARY ABOUT?: This PLSP provides a short summary of an original scientific article that presented results from the PRIMA study after 3.5 years of follow-up time. The original article was published in the European Journal of Cancer in 2023. The PRIMA study included adult patients with newly diagnosed advanced high-risk ovarian cancer whose tumors shrunk or became undetectable after treatment with chemotherapy with or without surgery. The PRIMA study evaluated how well the drug niraparib, also known as Zejula, worked at delaying or preventing ovarian cancer from coming back (recurring) or getting worse (progressing) compared with placebo (a substance with no effects that a doctor gives to a patient instead of a drug)...
March 19, 2024: Future Oncology
https://read.qxmd.com/read/38488039/evaluating-relugolix-for-the-treatment-of-prostate-cancer-in-real-world-settings-of-care-the-optyx-study-protocol
#13
REVIEW
Daniel E Spratt, Tanya Dorff, Rana R McKay, Benjamin H Lowentritt, Mark Fallick, Sergio C Gatoulis, Scott C Flanders, Ashley E Ross
OPTYX is a multi-center, prospective, observational study designed to further understand the actual experience of patients with advanced prostate cancer treated with relugolix (ORGOVYX® ), an oral androgen deprivation therapy (ADT), by collecting clinical and patient-reported outcomes from routine care settings. The study aims to enroll 1000 consented patients with advanced prostate cancer from community, academic and government operated clinical practices across the USA. At planned timepoints, real-world data analysis on treatment patterns, adherence and safety as well as health outcomes and health-related quality-of-life (HRQOL) after treatment discontinuation will be published in scientific peer-reviewed journals and presented at relevant conferences...
March 15, 2024: Future Oncology
https://read.qxmd.com/read/38482686/effect-of-multidisciplinary-cooperative-continuous-nursing-and-psychological-nursing-on-multiple-myeloma-with-a%C3%A2-peripherally-inserted-central-catheter
#14
JOURNAL ARTICLE
Dongliang Li, Fengfeng Sun, Yan Yang
Objective: This study was conducted to analyze the effectiveness of multidisciplinary cooperative continuous nursing combined with psychological nursing intervention in multiple myeloma (MM) patients undergoing peripherally inserted central catheter (PICC). Methods: The Numerical Pain Rating Scale (NPRS), Anxiety Self-Assessment Scale (SAS), Depression Self-Assessment Scale (SDS) and Revised Piper Fatigue Scale (PFS-R), Self-Care Ability Scale (ESCA), Quality of Life Core Questionnaire (QLQ-C30), incidence of unplanned extubation of PICC, total incidence of catheter-related complications and satisfaction with nursing were compared between the two groups of patients in a prospective study...
March 14, 2024: Future Oncology
https://read.qxmd.com/read/38456312/a-meta-analysis-of-predictive-value-of-blood-biomarkers-in-gestational-trophoblastic-neoplasia
#15
REVIEW
Ying Guo, Taohong Zhang, Xinyi He, Huiqiu Xu, Lisha Wang, Weihua Zhou, Li Gao, Ruifang An
Background: Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been reported to play a diagnostic and predictive role in gestational trophoblastic disease. However, the conclusions are still ambiguous. This meta-analysis aimed to evaluate the combined predictive value of NLR and PLR in the malignant progression of gestational trophoblastic disease. Method: Electronic databases including PubMed, Embase, the Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure, Wanfang and China Biomedical Literature Database were searched for the relevant literature published up to 1 October 2022...
March 8, 2024: Future Oncology
https://read.qxmd.com/read/38445372/response-to-first-line-pembrolizumab-in-metastatic-kras-mutated-non-small-cell-lung-cancer
#16
JOURNAL ARTICLE
Sabrina Rossi, Arianna Pagliaro, Giovanna Finocchiaro, Arianna Marinello, Laura Giordano, Emilio Bria, Alessio Stefani, Antonio Vitale, Luca Toschi, Ettore D'Argento, Armando Santoro
Aims: This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Methods: Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81). Results: A mutation in the KRAS gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in KRAS -mutated cases was longer than in wild-type cases (11...
March 6, 2024: Future Oncology
https://read.qxmd.com/read/38445361/design-of-a-single-center-phase-ii-trial-to-explore-the-efficacy-and-safety-of-r-isv-ro-%C3%A2-treatment-in-advanced-tumors
#17
REVIEW
Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yuchen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Rutian Li
Background: The authors' preclinical study has confirmed that RO adjuvant (composed of TLR 7 agonists [imiquimod/R837] and OX40 agonists) injected into local lesions induces the regression of both primary tumor and distant metastasis. The authors propose to realize local control and exert abscopal effect through an 'R-ISV-RO' in situ strategy plus anti-PD-1 monoclonal antibody in advanced tumors. Methods: This study is a single-center, exploratory, phase II trial to evaluate the efficacy and safety of R-ISV-RO plus anti-PD-1 monoclonal antibody in advanced tumors...
March 6, 2024: Future Oncology
https://read.qxmd.com/read/38440864/relationship-between-nurses-perceptions-and-financial-toxicity-management-in-the-public-health-insurance-system
#18
JOURNAL ARTICLE
Sena Yamamoto, Hideko Nakagoshi, Chiharu Kondoh, Yuichi Iwagami, Megumi Katayama, Ai Fukae, Mayuko Kakumen, Naoko Kodani, Atsuyo Kumagai, Chizuru Higashide, Chiharu Mizuta, Shunsuke Oyamada, Harue Arao
Aims: To describe nursing practices for financial toxicity management based on nurses' perceptions. Materials & methods: A survey was conducted with 615 oncology nurses in Japan, focusing on nurses' perspectives on the importance of financial toxicity, nursing practices to manage financial toxicity and factors inhibiting its management. Results: A total of 521 participated, of whom 266 respondents (51.1%) considered nurses' role important, and they engaged in a significantly higher proportion of nursing practices...
March 5, 2024: Future Oncology
https://read.qxmd.com/read/38426361/systematic-analysis-of-perivascular-epithelioid-cell-neoplasms-in-the-female-reproductive-tract-a-comprehensive-review
#19
REVIEW
Qiulin Cui, Cheng Li, Tongyi Huang, Jiaming Huang, Ming Chen
Perivascular epithelioid cell neoplasms (PEComas) are rare mesenchymal lesions, with gynecological PEComas accounting for just over a quarter of cases. Limited reports exist on gynecological PEComa, primarily treated with surgery; adjuvant therapy is considered in high-risk cases. This systematic review aims to summarize the origin and clinical, pathological and molecular characteristics of uterine PEComa, focusing on treatment options for gynecological PEComa. A comprehensive PubMed review of gynecological PEComa reports was conducted...
March 1, 2024: Future Oncology
https://read.qxmd.com/read/38421611/the-7-th-symposium-on-primary-breast-cancer-in-older-women
#20
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 29, 2024: Future Oncology
journal
journal
41162
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.